CTXR

Citius Pharmaceuticals, Inc. (CTXR) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on oncology, anti-infectives, and stem cell therapies. The company operates through wholly-owned subsidiary Leonard-Meron Biosciences, Inc. (LMB) and majority-owned subsidiaries Citius Oncology, Inc. (CTOR) and NoveCite, Inc. The company has generated no operating revenue to date and is preparing for the commercial launch of its FDA-approved product, LYMPHIR, in the fourth quarter of 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased to $8.79 million for the three months ended June 30, 2025, from $10.63 million in the prior year period. This was driven by a $1.14 million decrease in Research and Development (R&D) costs, primarily due to the completion of the Phase 3 trial for Mino-Lok and reduced validation costs for LYMPHIR.
• General and Administrative (G&A): G&A expenses decreased slightly to $4.45 million for the quarter compared to $4.81 million in the prior year. However, for the nine-month period, G&A increased to $14.63 million from $12.76 million due to higher pre-launch commercial activities for LYMPHIR.
• Other Income/Expense: The company recorded interest expense of $172,262 for the quarter, primarily related to a payment agreement with Eisai and a new note payable. This contrasts with the prior year which had no interest expense.
• Inventory: Inventory increased significantly to $17.2 million from $8.3 million at the end of the prior fiscal year, reflecting manufacturing of LYMPHIR commercial products.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The filing includes a substantial doubt about the company's ability to continue as a going concern. Management estimates available cash resources will fund operations only through September 2025. The company is actively engaged in capital raising initiatives.
• Commercial Launch: The company anticipates the U.S. commercial launch of LYMPHIR in the fourth quarter of 2025. Distribution agreements have been signed with Cardinal Health and Cencora.
• Significant Obligations:
  • Dr. Reddy's Milestone: A $27.5 million milestone payment became due upon FDA approval. As of June 30, 2025, a balance of $22.5 million remains due, with partial deferral agreed upon.
  • Eisai Milestone: A $5.9 million milestone payment is due, with a payment schedule agreed upon in March 2025.
  • Manufacturing Commitments: The company has minimum purchase commitments of approximately $18.3 million for drug substance and $4.5 million for finished product packaging through 2026.
• Financing Activity: During the nine months ended June 30, 2025, the company raised approximately $16.5 million in net proceeds from common stock offerings and $1 million from a note payable. Subsequent to the period end, Citius Oncology completed a public offering raising approximately $7.44 million in net proceeds.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of cash to fund operations beyond September 2025, given the negative working capital of $27.2 million.
• Milestone Payments: Confirm the status and funding source for the outstanding $22.5 million milestone payment to Dr. Reddy's and the scheduled payments to Eisai.
• LYMPHIR Launch: Monitor the timeline and execution of the Q4 2025 commercial launch and initial sales performance.
• Capital Raising: Track the success of ongoing equity financings by Citius Pharma and Citius Oncology to meet liquidity needs.
• Manufacturing Costs: Assess the impact of the $22.8 million in minimum purchase commitments for manufacturing on future cash flow.